ReviewJournal of molecular and cellular cardiology plus2026
MicroRNAs and SGLT2 inhibitors in cardiovascular disease: Shared pathways and emerging roles.
Review in Journal of molecular and cellular cardiology plus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs are non-coding RNA sequences capable of transport outside the cell to regulate essential cellular processes. They are able to induce structural changes implicated in prevalent cardiovascular conditions such as heart failure, atherosclerosis and myocardial ischemia. SGLT2 inhibitors are newer anti-diabetic drugs used in the prevention and treatment of cardiovascular disease, which modulate metabolic pathways shared with microRNAs. Direct evidence linking a mechanistic relationship between microRNAs and SGLT2 inhibitors is limited. However, they share multiple pathways affecting key cellular processes implicated in cardiovascular disease progression, such as fibrosis and inflammation. This mini-review explores the effects of microRNAs on cardiac disease, with potential implications in cardiovascular disease management. Shared mechanisms between microRNAs and SGLT2 inhibitors and subsequent impact on heart failure development will be emphasized throughout. Certain microRNAs implicated in cardiovascular disease could potentially serve as diagnostic and therapeutic targets. Future use of microRNA-based technologies may include biomarker panels of circulating microRNAs and exosomal delivery of therapeutic microRNAs. However, these technologies are not fully developed, as the majority of relevant studies are preclinical. Possible future applications of biomarker panels in precision medicine include diagnosis and risk stratification of patients for cardiac disease progression, monitoring response to heart failure therapies, and identification of microRNA targets for modulation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.